NEW YORK, May 20, 2026, 18:02 EDT
Jupiter Neurosciences shares swung sharply lower late Wednesday, giving back an early surge after the small-cap drug developer announced a proposed U.S. licensing deal for PharmAla Biotech’s MDMA-based ALA-002 candidate and, hours later, priced a $2 million stock offering.
The stock was last at $0.205, down roughly 37% from the prior close, after touching an intraday high of $0.67 and a low of $0.1809. More than 230 million shares had changed hands, an unusually heavy day for a company with a market value near $7.2 million.
The timing matters. Jupiter is trying to move into psychedelic-assisted psychiatry just as U.S. regulators are giving parts of the field a faster look; Reuters reported in April that the FDA awarded national priority vouchers to three companies after an executive order on psychedelic drugs with breakthrough-therapy status.
Jupiter and PharmAla said the non-binding term sheet gives Jupiter exclusive, perpetual U.S. rights to ALA-002, a next-generation, non-racemic MDMA Novel Chemical Entity, or NCE — a drug the FDA views as chemically distinct from previously approved products. PharmAla said the potential value exceeds $100 million, including $3.33 million upfront, milestones and royalties, while Jupiter is to place $600,000 in escrow and the parties have 90 days to reach definitive agreements.
MDMA is the compound widely known outside medicine as ecstasy. In this case, the companies are pitching ALA-002 as a controlled therapeutic candidate, not a consumer product, and said PharmAla would keep rights outside the United States.
Christer Rosén, Jupiter’s chairman and chief executive, called the proposed deal “strategically aligned” with the company’s CNS focus. Nicholas Kadysh, PharmAla’s founding CEO, said the arrangement would give ALA-002 a “dedicated U.S. development and commercialization home.” GlobeNewswire
Then came the financing. Jupiter said it entered a securities purchase agreement to sell 7,142,858 shares in a registered direct offering — a sale of shares directly to selected investors — for about $2 million in gross proceeds. D. Boral Capital is the exclusive placement agent, and the deal is expected to close around May 21, subject to customary conditions.
That offering helps explain the reversal. New share sales can bring in needed cash, but they also dilute existing holders by increasing the share count.
Jupiter’s balance sheet was already thin. In its first-quarter filing, the company reported $18,652 in product revenue, a $2.06 million net loss, $2.36 million in cash at March 31 and an accumulated deficit of $36.7 million. Management said those conditions raised substantial doubt about the company’s ability to continue as a going concern, meaning it may not have enough resources to operate for the next 12 months without more financing.
But the risks are larger than one financing. The ALA-002 pact is still a term sheet, not a completed acquisition of rights, and the company must clear due diligence, negotiate final documents and obtain any required approvals. Jupiter also faces Nasdaq compliance pressure: a February filing said the company had until Aug. 25, 2026, to regain compliance with the exchange’s $1 minimum bid price rule and $35 million market-value requirement.
The competitive backdrop is not empty. Compass Pathways, which is developing a psilocybin-based treatment program, and AtaiBeckley, another listed mental-health drug developer, remain much larger listed comparables, with market values of about $1.42 billion and $890 million, respectively, versus Jupiter’s roughly $7 million.
For now, traders have a deal headline, a funding round and a Nasdaq deadline. The next test is less dramatic: whether Jupiter can turn the PharmAla term sheet into binding documents and fund the work without further pressure on its shares.
